All In Biotech

Drug Trial Radar · NCT07179679

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

A Phase I Clinical Study to Evaluate the Safety and Pharmacokinetics of TQB2934 Subcutaneous Preparation for Injection in Subjects With Malignant Plasma Cell Tumors

Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Oct 2027

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody,and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells. TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • TQB2934 injection (subcutaneous injection)Drug

    TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen)double-specific antibody,and the isoform is Native Immunoglobulin G1 ( IgG1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak time (Tmax)Time frame: Within 120 hours after administration
  2. Peak drug concentration (Cmax)Time frame: Within 120 hours after administration
  3. Area under the plasma concentration-time curve (AUC0-last)Time frame: Within 120 hours after administration
  4. Elimination half-life (t1/2)Time frame: Within 120 hours after administration
  5. Apparent clearance (CL)Time frame: Within 120 hours after administration
  6. Adverse events(AEs)Time frame: Up to 24 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China · Not yet recruiting

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Nanjing Drum Tower hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • Nanchang University First Affiliated Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Recruiting

  • Heze Municipal Hospital

    Heze, Shandong, China · Not yet recruiting

  • Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan, China · Not yet recruiting

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.